# Lead-212 PSV359 Therapy for Patients With Solid Tumors

> **NCT06710756** · PHASE1,PHASE2 · RECRUITING · sponsor: **Perspective Therapeutics** · enrollment: 112 (estimated)

## Conditions studied

- Pancreatic Ductal Adenocarcinoma
- Gastric Cancer
- Esophageal Cancer
- Colorectal Cancer
- Ovarian Cancer
- Head and Neck Cancer
- Sarcoma
- Mesothelioma

## Interventions

- **DRUG:** [203Pb]Pb-PSV359
- **DRUG:** [212Pb]Pb-PSV359

## Key facts

- **NCT ID:** NCT06710756
- **Lead sponsor:** Perspective Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-28
- **Primary completion:** 2028-01-31
- **Final completion:** 2032-05-28
- **Target enrollment:** 112 (ESTIMATED)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06710756

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06710756, "Lead-212 PSV359 Therapy for Patients With Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06710756. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*